RegeneRx Biopharmaceuticals, Inc. · OTC:RGRX
RegeneRx Biopharmaceuticals — Shareholder Meeting (July 2008)
19 slides from RegeneRx Biopharmaceuticals's shareholder meeting presentation, Jul 2, 2008

Slide 1: 2008 Annual Shareholders' Meeting
2008 Annual Shareholders’ Meeting July 2, 2008

Slide 2: Forward Looking Statement
2 Forward Looking Statement This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Exampl

Slide 3: Our Mission
3 To develop and commercialize novel pharmaceutical products that prevent or repair tissue and organ damage caused by disease, trauma, or other pathology. Our Mission

Slide 4: Company Background
4 Company Background Unique peptide company addressing large markets and orphan indications having unmet medical needs - RGN-137 - Topical gel - RGN-259 - Sterile eye drop - RGN-352 - Parenteral (injectable) Robust clinical program - Three Phase II dermal trials underway - Phase II ophthalmic trial

Slide 5: Management
5 Management Dr. Allan Goldstein – Chairman & Chief Scientific Advisor - Founder of RegeneRx, Discoverer of T a 1 and Tß4 - Chairman of Biochemistry and Molecular Biology, George Washington Univ School of Medicine - Author of over 400 scientific articles; inventor of more than 25 U.S. Patents J.J. F

Slide 6: Scientific Advisory Board
6 Scientific Advisory Board Allan Goldstein, PhD – Chairman & Chief Scientific Advisor - Professor and Chair, Dept of Biochemistry and Molecular Bio, GWU Med School, Washington, DC Herve Byron, MD, MSc - Ophthalmologist in private practice, editorial board of several medical journals specializing in

Slide 7: 2007-2008 Highlights
7 2007-2008 Highlights Received two INDs to begin a Phase II ophthalmic wound healing clinical trial and a Phase IA parenteral (injectable) clinical trial, both of which are enrolling patients Implemented numeric naming for our current drug products to differentiate between formulations and create a

Slide 8: 2007-2008 Highlights
8 2007-2008 Highlights Numerous papers published on basic research and therapeutic potential of Tß4: – most notable was the cardiovascular research presented at an American Heart Association meeting in November highlighting Tß4’s cardio-protective capabilities in an ischemia-reperfusion pig model, f

Slide 9: 2007-2008 Highlights
9 2007-2008 Highlights RegeneRx executives gave corporate presentations at numerous industry and investment banking venues in 2007, including: – BIO 2007 Investor Forum – BIO 2007 Business Forum – 20th Annual Symposium on Advanced Wound Care – First Annual Symposium on Thymosins in Health and Diseas

Slide 10: Research and Development Collaborations
10 Research and Development Collaborations 18 Active Research Collaborations, Others in Discussion Ophthalmic repair U.S. Military (JG) Stem cell – cardiovascular European University Cosmeceuticals Mexico Dermal Company Ophthalmic mechanisms of repair Midwest University Medical School (GS) Renal fib

Slide 11: RegeneRx Technology Platform
11 RegeneRx Technology Platform Thymosin Beta 4 (Tß4) Naturally occurring, conserved molecule (identical across all species), found in every cell except red blood cells - highest concentration in blood platelets Key Actin regulator in mammals: – Actin plays central role in cell structure and movemen

Slide 12: Product Formulations and Targets
12 Product Formulations and Targets Multiple Formulations = Multiple Opportunities • Vitrectomy • Sjögren’s Dry Eye • Corneal Surgery • Recurrent Corneal Erosions • Acute M.I. • Ischemic Stroke • Crohn’s • EB • Ulcerative Colitis • Ischemic Renal Disease • Venous Statis Ulcers • EB • Diabetic Ulcers

Slide 13: Clinical Pipeline
13 Clinical Pipeline RGN Is Sponsoring 5 Clinical Trials for Multiple Indications Indications Preclinical Phase I Phase II Enrollment targeted Pressure Ulcers (72 patients) Venous Stasis Ulcers (72 patients) Epidermolysis Bullosa (36 patients) Corneal Wound Healing associated with diabetic vitrectom

Slide 14: Clinical Overview – RGN-137 (Dermal)
14 Clinical Overview – RGN-137 (Dermal) Phase I dermal safety – no dose-limiting AEs – 15 healthy volunteers Phase II Recurrent Pressure Ulcers – 72–patient trial ongoing – currently enrolling patients, up to 20 U.S. sites – Randomized, double-blind, placebo-controlled, dose-escalation, 84–day treat

Slide 15: Clinical Overview – RGN-259 (Ophthalmic) and RGN-352 (Parenteral)
15 Clinical Overview – RGN–259 (Ophthalmic) and RGN–352 (Parenteral) Phase II Corneal Wound Healing Post Vitrectomy – 48–patient trial – enrolling patients, 14 U.S. sites – Randomized, double–blind, placebo–controlled, dose–escalation, 14 day treatment period – Target enrollment completion: Q4 2008

Slide 16: IP Overview
16 IP Overview RegeneRx has strong patent portfolio addressing Tissue Protection & Repair opportunities Obtained world-wide intellectual property rights under an exclusive license from NIH in 1999 Filed over 60 patent applications worldwide related to Tß4, active fragments, compositions of matter, c

Slide 17: RegeneRx Business & Partnering Strategy
17 RegeneRx Business & Partnering Strategy Outsourcing business model – adds value, cost-effective - CROs conducting Phase II dermal trials, Phase II ophthalmic trial and Phase I parenteral trial - Use outside contractors for manufacturing, formulation, tox and pk studies, etc. • Tß4, analogues and

Slide 18: Summary
18 Summary Unique peptide drug candidate addresses multiple large and certain niche markets, all with unmet needs - Dermal, ophthalmic, parenteral indications (potential future myocardial infarction trial) 53+ scientific publications and presentations in peer-reviewed journals and at scientific meet

Slide 19: RegeneRx
REGENERX
Source: SEC EDGAR · 8-K filed Jul 2, 2008
More decks from RegeneRx Biopharmaceuticals, Inc.
Shareholder Meeting (November 2021)17 slides · November 2021
The Fall Investor Summit 201918 slides · Sep 16, 2019
Rodman & Renshaw 18th Annual Global Investment Conference 201628 slides · Sep 12, 2016
Shareholder Meeting (September 2014)15 slides · Sep 15, 2014
Shareholder Meeting (July 2010)13 slides · Jul 14, 2010
Investor Presentation (October 2008)31 slides · Oct 30, 2008